Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Zacks.com on MSN15h
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugViking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...
The team from Massachusetts Institute of Technology (MIT) have suggested that the technology could be useful for applications ...
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...
The "Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035 -- Distribution by Type of Device, Route ...
Mean time difference between IV and subcutaneous administration in the treatment chair served as the primary endpoint. Mean overall treatment experience time, drug administration time and pharmacy ...
AstraZeneca inks license pact with Alteogen for subcutaneous formulations of multiple oncology assets: Cambridge, UK Tuesday, March 18, 2025, 12:00 Hrs [IST] AstraZeneca, a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback